Prostate cancer and HRT

Andrew Huberman and Dr. Michael Eisenberg discuss the relationship between testosterone therapy and prostate cancer risk on the Huberman Lab. They address the myth that testosterone therapy increases the risk of prostate cancer. Historically, reducing testosterone levels was seen to cause regression in prostate cancer, leading to concerns about hormone replacement therapy increasing cancer risk. However, extensive longitudinal studies suggest that providing testosterone therapy does not increase prostate cancer risk. The saturation model explains that once testosterone reaches a certain threshold, adding more doesn't affect prostate cancer development because the receptors are already saturated 1.